Torii Pharmaceutical Co., Ltd.
TRXPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1,848,439.42 | 10,314,930.92 | 2,617,330.77 | -13,426,941.17 |
| FCF Yield | 0.00% | -0.00% | 0.00% | -0.00% |
| EV / EBITDA | 29,319,368.96 | 30,955,982.77 | 29,156,281.87 | 31,442,030.58 |
| Quality | ||||
| ROIC | 4.16% | 3.06% | 3.16% | 2.96% |
| Gross Margin | 44.20% | 41.65% | 47.81% | 51.80% |
| Cash Conversion Ratio | 0.54 | -0.76 | 0.42 | -0.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 7.31% | 5.16% | 5.45% | 3.00% |
| Free Cash Flow Growth | 203.59% | -256.10% | 503.58% | 86.25% |
| Safety | ||||
| Net Debt / EBITDA | -0.41 | -0.79 | -3.33 | -5.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.37 | 2.97 | 2.84 | 2.58 |
| Cash Conversion Cycle | 228.47 | 233.46 | 204.81 | 218.84 |